Full text is available at the source.
Modulation of gut microbiota to overcome resistance to immune checkpoint blockade in cancer immunotherapy
Changing gut bacteria to help cancer immunotherapy work better when it faces resistance
AI simplified
Abstract
Immune checkpoint inhibitors (ICIs) may face resistance in a significant portion of patients, prompting exploration into gut microbiota as a therapeutic strategy.
- A notable number of patients exhibit either primary or acquired resistance to therapies targeting CTLA-4 and PD-1/PD-L1.
- Current research highlights the potential of gut microbiota to enhance the effectiveness of immune checkpoint blockade therapies.
- Preclinical models and standardized microbiome analysis are being used to investigate the relationship between gut microbiota and immune responses to ICIs.
- Multi-omic approaches are advancing the understanding of how gut microbiota interacts with immune checkpoint inhibitors.
- Traditional Chinese medicine may serve as a microbiome modulator, potentially increasing sensitivity to immune checkpoint therapies.
AI simplified